Europe acute respiratory distress syndrome (ARDS) market is projected to register a substantial CAGR of 9.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029 Market Segmentation: Europe Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway and Rest of Europe) Industry Trends and Forecast to 2029 Some of the major factors for the market growth of Europe acute respiratory distress syndrome (ARDS) are: • Rise in the number of COVID-19 cases associated with ARDS Market Players: Some of the key market players for the Europe acute respiratory distress syndrome (ARDS) market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge AB. • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • F. Hoffmann-La Roche Ltd • Smiths Medical (part of ICU Medical, Inc.) • Drägerwerk AG & Co. KGaA • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd.

1 INTRODUCTION 21 1.1 OBJECTIVES OF THE STUDY 21 1.2 MARKET DEFINITION 21 1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 21 1.4 LIMITATIONS 23 1.5 MARKETS COVERED 23 2 MARKET SEGMENTATION 25 2.1 MARKETS COVERED 25 2.2 GEOGRAPHICAL SCOPE 26 2.3 YEARS CONSIDERED FOR THE STUDY 26 2.4 CURRENCY AND PRICING 26 2.5 DBMR TRIPOD DATA VALIDATION MODEL 27 2.6 MULTIVARIATE MODELLING 30 2.7 CAUSE LIFELINE CURVE IN EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 31 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32 2.9 DBMR MARKET POSITION GRID 33 2.10 MARKET END USER COVERAGE GRID 35 2.11 VENDOR SHARE ANALYSIS 36 2.12 SECONDARY SOURCES 37 2.13 ASSUMPTIONS 37 3 EXECUTIVE SUMMARY 38 4 PREMIUM INSIGHTS 40 4.1 PESTEL 41 4.2 PORTER'S FIVE FORCES 42 4.3 PIPELINE ANALYSIS 43 4.4 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 45 4.4.1 REGULATION IN EUROPE: 45 4.5 INSURANCE REIMBURSEMENT 47 4.5.1 CERN HEALTH INSURANCE SCHEME 47 5 MARKET OVERVIEW 48 5.1 DRIVERS 50 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 50 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 50 5.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 50 5.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 51 5.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 51 5.2 RESTRAINTS 52 5.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 52 5.2.2 HIGH COST OF DEVICE AND TREATMENTS 52 5.2.3 LACK OF SKILLED WORKFORCE 53 5.3 OPPORTUNITIES 53 5.3.1 GROWING GERIATRIC POPULATION 53 5.3.2 RISING HEALTHCARE EXPENDITURE 54 5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 54 5.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 55 5.4 CHALLENGES 55 5.4.1 STRINGENT RULES & REGULATIONS 55 5.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 56 6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 57 6.1 OVERVIEW 58 6.2 CORONAVIRUS DISEASE 2019 (COVID-19) 60 6.3 SEPSIS 61 6.4 INHALATION OF HARMFUL SUBSTANCES 61 6.5 SEVERE PNEUMONIA 62 6.6 OTHERS 62 7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 63 7.1 OVERVIEW 64 7.2 DIAGNOSIS 66 7.2.1 IMAGING TESTS 67 7.2.1.1 CHEST X-RAY 68 7.2.1.2 CT SCAN 68 7.2.1.3 ULTRASOUND 68 7.2.1.4 OTHERS 68 7.2.2 BLOOD TEST 68 7.2.3 RESPIRATORY RATE 68 7.2.4 SPO2 TEST 68 7.2.5 OTHERS 68 7.3 TREATMENT 68 7.3.1 MECHANICAL VENTILATION 69 7.3.1.1 HIGH-FLOW NASAL O2 70 7.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 70 7.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 70 7.3.1.4 PRONE POSITIVE VENTILATION 70 7.3.1.5 OTHERS 70 7.3.2 CORTICOSTEROIDS 70 7.3.2.1 METHYLPREDNISOLONE 71 7.3.2.2 DEXAMETHASONE 71 7.3.2.3 OTHERS 71 7.3.3 ANTIVIRAL MEDICATION 71 7.3.3.1 REMDESIVIR 72 7.3.3.2 COMBINATION DRUGS 72 7.3.3.3 OTHERS 72 7.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 72 7.3.5 TOCILIZUMAB 72 7.3.6 OTHERS 72 8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 73 8.1 OVERVIEW 74 8.2 PARENTERAL 76 8.2.1 INTRAVENOUS 77 8.2.2 INTRAMUSCULAR 77 8.3 ORAL 77 8.4 OTHERS 78 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 79 9.1 OVERVIEW 80 9.2 HOSPITALS 82 9.3 SPECIALTY CLINICS 83 9.4 HOME HEALTHCARE 83 9.5 OTHERS 83 10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 85 10.1 OVERVIEW 86 10.2 DIRECT TENDER 88 10.3 HOSPITAL PHARMACY 89 10.4 RETAIL PHARMACY 89 10.5 ONLINE PHARMACY 89 11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY 91 11.1 EUROPE 91 11.1.1 GERMANY 101 11.1.2 FRANCE 105 11.1.3 U.K. 109 11.1.4 ITALY 113 11.1.5 SPAIN 117 11.1.6 TURKEY 121 11.1.7 HUNGARY 125 11.1.8 NETHERLANDS 129 11.1.9 SWITZERLAND 133 11.1.10 AUSTRIA 137 11.1.11 LITHUANIA 141 11.1.12 POLAND 145 11.1.13 RUSSIA 149 11.1.14 IRELAND 153 11.1.15 NORWAY 157 11.1.16 REST OF EUROPE 161 12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 162 12.1 COMPANY SHARE ANALYSIS: EUROPE 162 13 SWOT ANALYSIS 163 14 COMPANY PROFILE 164 14.1 GILEAD SCIENCES INC. 164 14.1.1 COMPANY SNAPSHOT 164 14.1.2 REVENUS ANALYSIS 164 14.1.3 PRODUCT PORTFOLIO 165 14.1.4 RECENT DEVELOPMENT 165 14.2 TERUMO CORPORATION 166 14.2.1 COMPANY SNAPSHOT 166 14.2.2 REVENUS ANALYSIS 166 14.2.3 PRODUCT PORTFOLIO 167 14.2.4 RECENT DEVELOPMENT 167 14.3 GETINGE AB 168 14.3.1 COMPANY SNAPSHOT 168 14.3.2 REVENUS ANALYSIS 168 14.3.3 PRODUCT PORTFOLIO 169 14.3.4 RECENT DEVELOPMENT 169 14.4 LIVANOVA PLC 170 14.4.1 COMPANY SNAPSHOT 170 14.4.2 REVENUE ANALYSIS 170 14.4.3 PRODUCT PORTFOLIO 171 14.4.4 RECENT DEVELOPMENTS 171 14.5 MEDTRONIC 172 14.5.1 COMPANY SNAPSHOT 172 14.5.2 REVENUE ANALYSIS 172 14.5.3 PRODUCT PORTFOLIO 173 14.5.4 RECENT DEVELOPMENTS 173 14.6 ARMSTRONG MEDICAL 174 14.6.1 COMPANY SNAPSHOT 174 14.6.2 PRODUCT PORTFOLIO 174 14.6.3 RECENT DEVELOPMENT 174 14.7 DRÄGERWERK AG & CO. KGAA 175 14.7.1 COMPANY SNAPSHOT 175 14.7.2 REVENUE ANALYSIS 175 14.7.3 PRODUCT PORTFOLIO 176 14.7.4 RECENT DEVELOPMENTS 176 14.8 EUROSETS 177 14.8.1 COMPANY SNAPSHOT 177 14.8.2 PRODUCT PORTFOLIO 177 14.8.3 RECENT DEVELOPMENT 177 14.9 F. HOFFMANN-LA ROCHE LTD 178 14.9.1 COMPANY SNAPSHOT 178 14.9.2 RECENT ANALYSIS 178 14.9.3 PRODUCT PORTFOLIO 179 14.9.4 RECENT DEVELOPMENTS 179 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 180 14.10.1 COMPANY SNAPSHOT 180 14.10.2 REVENUE ANALYSIS 180 14.10.3 PRODUCT PORTFOLIO 181 14.10.4 RECENT DEVELOPMENTS 181 14.11 FRESENIUS SE & CO. KGAA 182 14.11.1 COMPANY SNAPSHOT 182 14.11.2 REVENUS ANALYSIS 182 14.11.3 PRODUCT PORTFOLIO 183 14.11.4 RECENT DEVELOPMENTS 183 14.12 HAMILTON MEDICAL 184 14.12.1 COMPANY SNAPSHOT 184 14.12.2 PRODUCT PORTFOLIO 184 14.12.3 RECENT DEVELOPMENT 184 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 185 14.13.1 COMPANY SNAPSHOT 185 14.13.2 PRODUCT PORTFOLIO 185 14.13.3 RECENT DEVELOPMENT 185 14.14 PFIZER INC. 186 14.14.1 COMPANY SNAPSHOT 186 14.14.2 REVENUS ANALYSIS 186 14.14.3 PRODUCT PORTFOLIO 187 14.14.4 RECENT DEVELOPMENT 187 14.15 RESMED 188 14.15.1 COMPANY SNAPSHOT 188 14.15.2 REVENUE ANALYSIS 188 14.15.3 PRODUCT PORTFOLIO 189 14.15.4 RECENT DEVELOPMENT 189 14.16 SMITHS MEDICAL 190 14.16.1 COMPANY SNAPSHOT 190 14.16.2 REVENUS ANALYSIS 190 14.16.3 PRODUCT PORTFOLIO 191 14.16.4 RECENT DEVELOPMENTS 191 15 QUESTIONNAIRE 192 16 RELATED REPORTS 196